Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Circulating tumor DNA dynamics in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer assessed using an ultrasensitive tumor-informed assay.

Serial ctDNA was measured with a whole-genome tumor-informed assay in stage II-III hormone receptor-positive, HER2-negative early breast cancer and examined against recurrence. A Personalis author affiliation is on the PubMed record.

ESMO OpenPubMed 42617422DOI 10.1016/j.esmoop.2026.108360